NCT06584006View on ClinicalTrials.gov

Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

February 29, 2028

Conditions
Hematological MalignancyLymphocytopenia
Interventions
DRUG

Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections

Thymalfasin for injection 1.6mg subcutaneous injection once daily (qd) for 7 days, and Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.

DRUG

Recombinant Human Interleukin-2 Injections

Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.

Trial Locations (1)

Unknown

RECRUITING

Zhijuan Lin, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER